查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1555712

注射奈米藥物市場，按產品類型、治療領域、給藥途徑、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Injectable Nanomedicines Market, By Product Type, By Therapeutic Area, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 388 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年注射奈米藥物市場規模為6.5456億美元，2024年至2032年複合年成長率為8.3%。

注射奈米藥物市場-市場動態

慢性病的日益普及推動了對注射奈米藥物的需求

癌症、糖尿病、心血管疾病和自體免疫疾病等慢性病的盛行率不斷上升，推動了對創新治療方法的需求，包括注射奈米藥物。可注射的奈米藥物可以設計用於將藥物專門輸送到患病組織或細胞，從而減少對健康組織的副作用。美國食品藥物管理局 (FDA) 在塑造注射奈米藥物市場方面發揮關鍵作用。 FDA 嚴格的核准流程確保了這些創新療法的安全性和有效性，但也為尋求市場進入的公司帶來了挑戰。奈米藥物可以提供受控和持續的藥物釋放，這對於治療慢性疾病至關重要。這有助於長期維持治療藥物水平，減少注射頻率並提高患者依從性。據世界衛生組織(WHO)稱，在印度，21%的老年人患有至少一種慢性病，其中農村地區為17%，城市地區為29%。在美國，近 95% 的 60 歲及以上成年人至少患有一種慢性病，近 80% 的人患有兩種或兩種以上。

注射奈米藥物市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 8.3% 左右的複合年成長率成長

根據產品類型細分，預計聚合物奈米粒子將在 2023 年顯示最大的市場佔有率

根據治療領域細分，腫瘤學是2023年的主導類型

根據最終用戶細分，醫院是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

注射奈米藥物市場-細分分析：

全球注射奈米藥物市場根據產品類型、治療領域、給藥途徑、最終用戶和地區進行細分。

根據產品類型，市場分為五類：脂質體、聚合物奈米顆粒、金屬奈米顆粒、樹枝狀聚合物和膠束。在整個預測期內，預計對聚合物奈米顆粒的需求將進一步增加，這種需求在過去幾年中已顯著成長。奈米技術 (NP) 透過將科學極限推向奈米醫學產業革命性發現的前沿，正在影響癌症、神經系統疾病和心血管疾病等學科。亞太地區政府在奈米醫學研發（R&D）的目標是成為該領域的領導者並解決某些社會需求。

根據應用，市場分為四類：醫院、診所、研究實驗室和其他。可注射的奈米藥物可以被設計為將藥物直接輸送到特定的細胞或組織，例如靶向癌細胞，同時保護健康細胞。這種精確度減少了副作用並提高了治療效果。奈米藥物可以根據患者的個別需求進行客製化，從而製定更個人化和有效的治療計劃。這對於治療癌症等複雜疾病特別有益。

注射奈米藥物市場 - 地理洞察

從地理位置來看，北美和歐洲由於強大的研究基礎設施和支持性監管框架而處於領先地區。然而，由於醫療保健投資的增加和先進醫療技術的採用，亞太地區的新興市場正在快速成長。由於其強大的醫療基礎設施、廣泛的研發能力和先進醫療技術的高度採用，北美是注射奈米藥物市場的重要參與者。美國在該地區處於領先地位，這得益於奈米技術研究的強勁資金以及重要製藥和生物技術公司的強大影響力。癌症、糖尿病和心血管疾病等慢性疾病的高盛行率也支持了該市場，這需要奈米藥物等先進的治療選擇。歐洲藥品管理局 (EMA) 是監督該地區奈米藥物核准和商業化的主要監管機構。 EMA 的法規通常被認為是嚴格的，但它們為公司開發和銷售奈米藥物提供了明確的框架。歐盟的計劃，例如「地平線2020」計劃，在支持奈米醫學研究和創新方面也發揮了至關重要的作用。

注射奈米藥物市場-競爭格局：

注射奈米藥物市場的主要參與者包括輝瑞公司、阿斯特捷利康公司、賽諾菲公司、強生公司、Moderna公司、諾華公司等。以加速開發和應用。輝瑞利用合作夥伴關係和收購來增強其注射奈米藥物產品組合，重點關注脂質體製劑和基於奈米顆粒的療法。諾華在研發方面投入巨資，並與學術機構合作開發下一代奈米藥物，特別是在標靶藥物傳輸方面。百時美施貴寶公司強調奈米技術來增強其生物製劑的交付，特別是在腫瘤學領域，擁有強大的奈米藥物候選產品管線。阿斯特捷利康利用奈米技術進行標靶藥物輸送，特別是在腫瘤學領域，並投資於夥伴關係和合作以擴大其奈米醫學能力。

最新進展：

2021 年 3 月，PACIRA Biosciences, Inc. 的 Exparel（布比卡因脂質體注射混懸液）獲得 FDA 批准，這是一種用於兒科患者的新藥物應用。

2021年3月，Jazz Pharmaceutical 宣布追加 Vyxeos（柔紅黴素和阿糖胞苷）用於治療繼發性急性骨髓性白血病。

目錄

第1章：注射奈米藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按產品類型分類的注射奈米藥物市場片段
    • 按治療領域分類的注射奈米藥物市場片段
    • 依給藥途徑分類的注射奈米藥物市場片段
    • 最終用戶的注射奈米藥物市場片段
    • 按國家/地區分類的注射奈米藥物市場片段
    • 按地區分類的注射奈米藥物市場片段
  • 競爭洞察

第 3 章：注射奈米藥物主要市場趨勢

  • 注射奈米藥物市場促進因素
    • 市場促進因素的影響分析
  • 注射奈米藥物市場限制
    • 市場限制影響分析
  • 注射奈米藥物市場機會
  • 注射奈米藥物市場未來趨勢

第 4 章：注射奈米藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：注射奈米藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：注射奈米藥物市場格局

  • 2023 年注射奈米藥物市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：注射奈米藥物市場 - 按產品類型

  • 概述
    • 按產品類型分類的細分市場佔有率分析
    • 脂質體
    • 聚合物奈米顆粒
    • 金屬奈米粒子
    • 樹枝狀聚合物
    • 膠束

第 8 章：注射奈米藥物市場 - 依治療領域

  • 概述
    • 按治療領域分類的細分市場佔有率分析
    • 腫瘤學
    • 心血管疾病
    • 神經系統疾病
    • 傳染病
    • 自體免疫疾病

第 9 章：注射奈米藥物市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 靜脈 (IV) 注射
    • 皮下注射
    • 肌肉內注射
    • 鞘內注射

第 10 章：注射奈米藥物市場 - 按最終用戶

  • 概述
    • 按治療領域分類的細分市場佔有率分析
    • 醫院
    • 診所
    • 研究實驗室
    • 其他

第 11 章：注射奈米藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美注射奈米藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按產品類型）
    • 北美市場規模與預測（按治療領域）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲注射奈米藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按產品類型）
    • 歐洲市場規模與預測（按治療領域）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區注射奈米藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（依產品類型）
    • 按治療領域分類的亞太市場規模和預測
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲注射奈米藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按產品類型）
    • 拉丁美洲市場規模與預測（按治療領域）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲注射奈米藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按產品類型）
    • 中東和非洲市場規模及預測（按治療領域）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 注射奈米藥物產業

  • 競爭儀表板
  • 公司簡介
    • Pfizer Inc.
    • AstraZeneca PLC
    • Johnson & Johnson
    • Sanofi
    • Merck & Co., Inc.
    • Moderna, Inc.
    • Amgen Inc.
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb
    • Teva Pharmaceutical Industries Ltd.
    • Nanobiotix SA
    • CytImmune Sciences, Inc.
    • BIND Therapeutics, Inc.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3689

REPORT HIGHLIGHT

Injectable Nanomedicines Market size was valued at USD 654.56 million in 2023, expanding at a CAGR of 8.3% from 2024 to 2032.

The Injectable Nanomedicines market involves the development, production, and commercialization of nanoscale drugs that are administered via injection. These nanomedicines leverage the unique properties of nanoparticles to enhance drug delivery, targeting, and efficacy, particularly in treating diseases such as cancer, cardiovascular disorders, and infectious diseases. Key drivers of the market include advancements in nanotechnology, increased prevalence of chronic diseases, and the demand for targeted therapies that reduce side effects. Additionally, government support for nanomedicine research and development, along with growing investments from pharmaceutical companies, is propelling market growth. Challenges in the market include high production costs, regulatory complexities, and potential safety concerns related to the long-term effects of nanoparticles on the human body. Despite these hurdles, the market is expected to grow significantly due to the increasing number of nanomedicine products in the pipeline and their promising therapeutic outcomes.

Injectable Nanomedicines Market- Market Dynamics

The increasing prevalence of chronic diseases driving the need for injectable nanomedicines

The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders is driving the need for innovative treatment approaches, including injectable nanomedicines. Injectable nanomedicines can be designed to deliver drugs specifically to diseased tissues or cells, reducing the side effects on healthy tissues. The U.S. Food and Drug Administration (FDA) plays a pivotal role in shaping the injectable nanomedicine market. The FDA's stringent approval process ensures the safety and efficacy of these innovative therapies, but it also poses a challenge for companies seeking market entry. Nanomedicines can provide controlled and sustained drug release, which is critical for managing chronic diseases. This helps in maintaining therapeutic drug levels over an extended period, reducing the frequency of injections and improving patient compliance. According to the World Health Organization (WHO), In India, 21% of the elderly have at least one chronic disease, with 17% in rural areas and 29% in urban areas. In the US, nearly 95% of adults 60 and older have at least one chronic condition, and nearly 80% have two or more.

Injectable Nanomedicines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2024-2032)

Based on product type segmentation, Polymeric Nanoparticles were predicted to show maximum market share in the year 2023

Based on Therapeutic Area segmentation, Oncology was the leading type in 2023

Based on End User segmentation, Hospitals were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Injectable Nanomedicines Market- Segmentation Analysis:

The Global Injectable Nanomedicines Market is segmented based on Product Type, Therapeutic Area, Route of Administration, End User, and Region.

The market is divided into five categories based on product type: Liposomes, Polymeric Nanoparticles, Metal Nanoparticles, Dendrimers, and Micelles. Throughout the projection period, there is expected to be a further increase in demand for polymeric nanoparticles, which has grown significantly in the last few years. Nanotechnology (NP) is influencing disciplines such as cancer, neurological disorders, and cardiovascular diseases by pushing scientific limits to the forefront of revolutionary discoveries for the nanomedicine business. The goal of the Asia Pacific government's research and development (R&D) in nanomedicine is to be a leader in the field and to solve certain social requirements.

The market is divided into four categories based on application: Hospitals, Clinics, Research Laboratories, and Others. Injectable nanomedicines can be engineered to deliver drugs directly to specific cells or tissues, such as targeting cancer cells while sparing healthy ones. This precision reduces side effects and increases treatment efficacy. Nanomedicines can be tailored to the individual patient's needs, allowing for more personalized and effective treatment plans. This can be particularly beneficial in treating complex diseases like cancer.

Injectable Nanomedicines Market- Geographical Insights

Geographically, North America and Europe are leading regions due to robust research infrastructure and supportive regulatory frameworks. However, emerging markets in Asia-Pacific are witnessing rapid growth due to increasing healthcare investments and the adoption of advanced medical technologies. North America is a significant player in the injectable nanomedicines market, driven by its strong healthcare infrastructure, extensive R&D capabilities, and high adoption of advanced medical technologies. The United States leads the region, supported by robust funding for nanotechnology research and a strong presence of key pharmaceutical and biotech companies. The market is also bolstered by a high prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions, which necessitate advanced therapeutic options like nanomedicines. The European Medicines Agency (EMA) is the primary regulatory body overseeing the approval and commercialization of nanomedicines in the region. The EMA's regulations are often seen as rigorous, but they provide a clear framework for companies to develop and market nanomedicines. The European Union's initiatives, such as the Horizon 2020 program, have also played a crucial role in supporting nanomedicine research and innovation.

Injectable Nanomedicines Market- Competitive Landscape:

Major players in the Injectable Nanomedicines Market include Pfizer Inc., AstraZeneca PLC, Sanofi, Johnson & Johnson, Moderna, Inc., Novartis AG etc. Companies are increasingly collaborating with academic institutions, research organizations, and other pharmaceutical companies to accelerate the development and commercialization of nanomedicines. Pfizer leverages partnerships and acquisitions to enhance its injectable nanomedicine portfolio, focusing on liposomal formulations and nanoparticle-based therapies. Novartis invests heavily in R&D and collaborates with academic institutions to develop next-generation nanomedicines, particularly in targeted drug delivery. Bristol-Myers Squibb Company emphasizes nanotechnology to enhance the delivery of its biologics, particularly in oncology, with a strong pipeline of nanomedicine candidates. AstraZeneca uses nanotechnology for targeted drug delivery, particularly in oncology, and invests in partnerships and collaborations to expand its nanomedicine capabilities.

Recent Developments:

In March 2021, PACIRA Biosciences, Inc. Got FDA Approval For Exparel (Bupivacaine Liposome Injectable Suspension) Which Is A New Drug Application In Pediatric Patients.

In March 2021, Jazz Pharmaceutical Announced Additional Vyxeos (Daunorubicin And Cytarabine) For The Treatment Of Secondary Acute Myeloid Leukemia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INJECTABLE NANOMEDICINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Sanofi
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb
  • Teva Pharmaceutical Industries Ltd.
  • Nanobiotix SA
  • CytImmune Sciences, Inc.
  • BIND Therapeutics, Inc.
  • Others

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Liposomes
  • Polymeric Nanoparticles
  • Metal Nanoparticles
  • Dendrimers
  • Micelles

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY THERAPEUTIC AREA - MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Autoimmune Diseases

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV) Injection
  • Subcutaneous Injection
  • Intramuscular Injection
  • Intrathecal Injection

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Research Laboratories
  • Others

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Injectable Nanomedicines Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Injectable Nanomedicines Market Snippet by Product Type
    • 2.1.2. Injectable Nanomedicines Market Snippet by Therapeutic Area
    • 2.1.3. Injectable Nanomedicines Market Snippet by Route of Administration
    • 2.1.4. Injectable Nanomedicines Market Snippet by End User
    • 2.1.5. Injectable Nanomedicines Market Snippet by Country
    • 2.1.6. Injectable Nanomedicines Market Snippet by Region
  • 2.2. Competitive Insights

3. Injectable Nanomedicines Key Market Trends

  • 3.1. Injectable Nanomedicines Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Injectable Nanomedicines Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Injectable Nanomedicines Market Opportunities
  • 3.4. Injectable Nanomedicines Market Future Trends

4. Injectable Nanomedicines Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Injectable Nanomedicines Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Injectable Nanomedicines Market Landscape

  • 6.1. Injectable Nanomedicines Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Injectable Nanomedicines Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Liposomes
    • 7.1.3. Polymeric Nanoparticles
    • 7.1.4. Metal Nanoparticles
    • 7.1.5. Dendrimers
    • 7.1.6. Micelles

8. Injectable Nanomedicines Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Neurological Disorders
    • 8.1.5. Infectious Diseases
    • 8.1.6. Autoimmune Diseases

9. Injectable Nanomedicines Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intravenous (IV) Injection
    • 9.1.3. Subcutaneous Injection
    • 9.1.4. Intramuscular Injection
    • 9.1.5. Intrathecal Injection

10. Injectable Nanomedicines Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Laboratories
    • 10.1.5. Others

11. Injectable Nanomedicines Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Injectable Nanomedicines Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Injectable Nanomedicines Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Injectable Nanomedicines Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Injectable Nanomedicines Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Injectable Nanomedicines Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Injectable Nanomedicines Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. AstraZeneca PLC
    • 12.2.3. Johnson & Johnson
    • 12.2.4. Sanofi
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. Moderna, Inc.
    • 12.2.7. Amgen Inc.
    • 12.2.8. Novartis AG
    • 12.2.9. F. Hoffmann-La Roche AG
    • 12.2.10. Gilead Sciences, Inc.
    • 12.2.11. Bristol-Myers Squibb
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Nanobiotix SA
    • 12.2.14. CytImmune Sciences, Inc.
    • 12.2.15. BIND Therapeutics, Inc.
    • 12.2.16. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us